Testing azithromycin in chronic lung disease with frequent flare-ups
Part of Lungs & breathing clinical trials.
This Phase 4 study tests whether a long course of azithromycin can reduce flare-ups in people with chronic obstructive pulmonary disease (COPD) who have had recent exacerbations. It also looks at mucus properties and how flare-ups happen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 40 to 85
- Have COPD diagnosed for at least 1 year and be on the best guideline-based treatment for your severity
- Have had at least 3 flare-ups in the last 12 months, or at least 1 severe flare-up needing hospital care
- Be able to produce sputum (phlegm)—either naturally or after induction—for testing
- Have a heart rhythm test (ECG) within safe limits (QTC less than 450 ms for men, 470 ms for women)
- Not have taken azithromycin in the past 3 months and not be allergic to azithromycin or similar antibiotics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study looks at optimizing how people with COPD take azithromycin to reduce flare-ups (exacerbations). If you already take azithromycin regularly, the trial may test ways to improve how it’s used safely.
This Phase 3 trial tests whether the antibiotic azithromycin can improve chronic sinus problems where there is persistent pus and swelling. It’s for adults who have not improved despite at least two prior antibiotics.
This study compares two medications, roflumilast and azithromycin, to see which is better at reducing COPD flare-ups (also called exacerbations) in people with severe COPD and chronic bronchitis. If it works, it could help you have fewer flare-ups and feel better day to day.
This study tests whether a common antibiotic called azithromycin can help prevent flare-ups (sudden worsening) of bronchiectasis—a lung condition where airways become permanently enlarged and damaged. Patients will take azithromycin or a placebo for 12 months to see if it reduces how often they get sick.
This trial tests whether giving a low dose of azithromycin (an antibiotic) can prevent lung infections in young children with structural lung damage or congenital lung/airway malformations. The goal is to reduce infections and keep lungs healthier.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.